Page last updated: 2024-08-07 16:33:09
Alpha-1A adrenergic receptor
An alpha-1A adrenergic receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P35348]
Synonyms
Alpha-1A adrenoreceptor;
Alpha-1A adrenoceptor;
Alpha-1C adrenergic receptor;
Alpha-adrenergic receptor 1c
Research
Bioassay Publications (168)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 11 (6.55) | 18.7374 |
| 1990's | 27 (16.07) | 18.2507 |
| 2000's | 62 (36.90) | 29.6817 |
| 2010's | 59 (35.12) | 24.3611 |
| 2020's | 9 (5.36) | 2.80 |
Compounds (136)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 8-hydroxy-2-(di-n-propylamino)tetralin | Homo sapiens (human) | Ki | 0.9797 | 9 | 9 |
| 6-fluoronorepinephrine | Homo sapiens (human) | Ki | 1.5000 | 1 | 1 |
| alfuzosin | Homo sapiens (human) | IC50 | 0.0230 | 1 | 1 |
| alfuzosin | Homo sapiens (human) | Ki | 0.0091 | 2 | 2 |
| amlodipine | Homo sapiens (human) | Ki | 2.3440 | 1 | 1 |
| apraclonidine | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| atenolol | Homo sapiens (human) | IC50 | 0.2300 | 1 | 1 |
| azelastine | Homo sapiens (human) | Ki | 0.0501 | 3 | 3 |
| bmy 7378 | Homo sapiens (human) | Ki | 0.3150 | 15 | 17 |
| bunazosin | Homo sapiens (human) | IC50 | 0.0012 | 1 | 1 |
| cisapride | Homo sapiens (human) | IC50 | 0.0300 | 2 | 2 |
| clonidine | Homo sapiens (human) | Ki | 0.3428 | 3 | 3 |
| doxazosin | Homo sapiens (human) | Ki | 0.0015 | 5 | 5 |
| ebastine | Homo sapiens (human) | IC50 | 0.1830 | 1 | 2 |
| haloperidol | Homo sapiens (human) | Ki | 0.0124 | 2 | 2 |
| mianserin | Homo sapiens (human) | IC50 | 0.4074 | 2 | 2 |
| mirtazapine | Homo sapiens (human) | IC50 | 3.1623 | 1 | 1 |
| naftopidil | Homo sapiens (human) | IC50 | 0.5550 | 2 | 2 |
| naftopidil | Homo sapiens (human) | Ki | 0.0037 | 1 | 1 |
| nan 190 | Homo sapiens (human) | Ki | 0.0003 | 1 | 1 |
| oxymetazoline | Homo sapiens (human) | Ki | 0.1297 | 3 | 3 |
| moxonidine | Homo sapiens (human) | Ki | 15.5000 | 2 | 2 |
| prazosin | Homo sapiens (human) | IC50 | 0.0006 | 4 | 4 |
| prazosin | Homo sapiens (human) | Ki | 0.0027 | 18 | 21 |
| propranolol | Homo sapiens (human) | IC50 | 5.0119 | 1 | 1 |
| quetiapine | Homo sapiens (human) | Ki | 0.0232 | 3 | 3 |
| risperidone | Homo sapiens (human) | IC50 | 0.0105 | 5 | 5 |
| risperidone | Homo sapiens (human) | Ki | 0.0050 | 6 | 6 |
| rizatriptan | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sumatriptan | Homo sapiens (human) | IC50 | 10.0000 | 1 | 2 |
| terazosin | Homo sapiens (human) | IC50 | 0.0050 | 1 | 1 |
| terazosin | Homo sapiens (human) | Ki | 0.0633 | 12 | 17 |
| terfenadine | Homo sapiens (human) | IC50 | 2.3400 | 1 | 2 |
| 5-methylurapidil | Homo sapiens (human) | Ki | 0.0011 | 3 | 3 |
| n-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-n-(2-pyridinyl)cyclohexanecarboxamide | Homo sapiens (human) | Ki | 0.0190 | 4 | 4 |
| wb 4101 | Homo sapiens (human) | IC50 | 0.0010 | 2 | 2 |
| wb 4101 | Homo sapiens (human) | Ki | 0.0004 | 9 | 9 |
| xylometazoline | Homo sapiens (human) | Ki | 0.0910 | 2 | 2 |
| zotepine | Homo sapiens (human) | Ki | 0.0034 | 1 | 1 |
| phentolamine | Homo sapiens (human) | IC50 | 0.0011 | 1 | 1 |
| phentolamine | Homo sapiens (human) | Ki | 0.0044 | 4 | 4 |
| phenylephrine | Homo sapiens (human) | Ki | 0.1622 | 1 | 1 |
| yohimbine | Homo sapiens (human) | Ki | 1.0570 | 1 | 1 |
| indopan | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| canadine, (s)-isomer | Homo sapiens (human) | IC50 | 5.4000 | 1 | 1 |
| pizotyline | Homo sapiens (human) | Ki | 0.0750 | 1 | 1 |
| indoramin | Homo sapiens (human) | Ki | 0.0038 | 2 | 2 |
| idazoxan | Homo sapiens (human) | IC50 | 2.8840 | 1 | 1 |
| ipsapirone | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
| ipsapirone | Homo sapiens (human) | Ki | 0.1580 | 2 | 2 |
| sertindole | Homo sapiens (human) | Ki | 0.0018 | 1 | 1 |
| niguldipine | Homo sapiens (human) | Ki | 0.1655 | 3 | 4 |
| aripiprazole | Homo sapiens (human) | IC50 | 0.1700 | 3 | 3 |
| aripiprazole | Homo sapiens (human) | Ki | 0.0330 | 2 | 2 |
| ziprasidone | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| ziprasidone | Homo sapiens (human) | Ki | 0.0090 | 4 | 4 |
| corynanthine | Homo sapiens (human) | Ki | 0.1420 | 1 | 1 |
| way 100635 | Homo sapiens (human) | Ki | 0.0200 | 1 | 1 |
| gr 127935 | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| roemerine | Homo sapiens (human) | Ki | 0.2512 | 1 | 1 |
| pramipexole | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| sk&f 104078 | Homo sapiens (human) | Ki | 0.0330 | 1 | 1 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | Homo sapiens (human) | Ki | 0.0560 | 1 | 1 |
| sk&f 86466 | Homo sapiens (human) | Ki | 0.4490 | 1 | 1 |
| sk&f 104856 | Homo sapiens (human) | Ki | 0.0324 | 3 | 3 |
| tamsulosin | Homo sapiens (human) | IC50 | 0.0013 | 2 | 2 |
| tamsulosin | Homo sapiens (human) | Ki | 0.0017 | 9 | 11 |
| cyclazosin | Homo sapiens (human) | Ki | 0.0138 | 4 | 4 |
| sc 53116 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sc 53116 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| rec 15-2739 | Homo sapiens (human) | Ki | 0.0007 | 2 | 2 |
| asenapine | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| abanoquil | Homo sapiens (human) | Ki | 0.0000 | 1 | 1 |
| 3-fluoronorepinephrine | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| 1-(3-(4-chlorobenzoyl)propyl)-4-hydroxy-4-(4-chlorophenyl)piperidine | Homo sapiens (human) | Ki | 0.1500 | 1 | 1 |
| nantenine, (+-)-isomer | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
| latrepirdine | Homo sapiens (human) | Ki | 0.0603 | 1 | 1 |
| eptapirone | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| bmy 7378 | Homo sapiens (human) | Ki | 0.2247 | 3 | 3 |
| adenosine-5'-(n-ethylcarboxamide) | Homo sapiens (human) | Ki | 0.0122 | 1 | 1 |
| rauwolscine | Homo sapiens (human) | Ki | 4.4000 | 1 | 1 |
| mitragynine | Homo sapiens (human) | Ki | 1.3400 | 1 | 1 |
| 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | Homo sapiens (human) | Ki | 0.4480 | 1 | 1 |
| bp 897 | Homo sapiens (human) | Ki | 0.0130 | 3 | 3 |
| rs 100329 | Homo sapiens (human) | Ki | 0.0003 | 1 | 1 |
| rs 17053 | Homo sapiens (human) | Ki | 0.0007 | 2 | 2 |
| 3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1,5-dihydropyrimido[5,4-b]indole-2,4-dione | Homo sapiens (human) | Ki | 928,837,500,000,000.0000 | 4 | 4 |
| a 61603 | Homo sapiens (human) | Ki | 1.3490 | 1 | 1 |
| le 300 | Homo sapiens (human) | Ki | 0.0110 | 1 | 1 |
| harmine | Homo sapiens (human) | Ki | 3.8733 | 2 | 3 |
| l 745870 | Homo sapiens (human) | Ki | 2.2000 | 1 | 1 |
| silodosin | Homo sapiens (human) | IC50 | 0.0018 | 2 | 2 |
| silodosin | Homo sapiens (human) | Ki | 0.0000 | 1 | 1 |
| ag 556 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| ro 25-6981 | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| dexniguldipine | Homo sapiens (human) | Ki | 0.1810 | 3 | 5 |
| vilazodone | Homo sapiens (human) | IC50 | 1.9800 | 1 | 1 |
| n-demethylloperamide | Homo sapiens (human) | Ki | 0.0099 | 1 | 1 |
| ro 70-0004 | Homo sapiens (human) | Ki | 0.0011 | 2 | 2 |
| 10,10-bis((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone | Homo sapiens (human) | Ki | 2.5000 | 2 | 2 |
| fauc 346 | Homo sapiens (human) | Ki | 0.0150 | 1 | 1 |
| 4-(3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl)-1-(4-fluorophenyl)butan-1-one | Homo sapiens (human) | Ki | 0.0744 | 1 | 2 |
| pnu 96415e | Homo sapiens (human) | Ki | 0.0380 | 1 | 1 |
| n-(4-((4-(dimethylamino)quinazolin-2-yl)amino)cyclohexyl)-3,4-difluorobenzamide hydrochloride | Homo sapiens (human) | IC50 | 0.3000 | 1 | 1 |
| 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | Homo sapiens (human) | Ki | 0.0180 | 1 | 1 |
| vortioxetine | Homo sapiens (human) | Ki | 0.0260 | 1 | 1 |
| sb-656104-a | Homo sapiens (human) | Ki | 0.2188 | 1 | 1 |
| tert-butyl peroxybenzoate | Homo sapiens (human) | Ki | 0.0110 | 1 | 1 |
| snap 6201 | Homo sapiens (human) | Ki | 0.0002 | 1 | 2 |
| 77-lh-28-1 | Homo sapiens (human) | Ki | 0.4365 | 1 | 1 |
| fauc 365 | Homo sapiens (human) | Ki | 0.9133 | 3 | 3 |
| fauc 113 | Homo sapiens (human) | Ki | 0.0036 | 1 | 1 |
| snap7941 | Homo sapiens (human) | Ki | 0.0400 | 1 | 1 |
| sp 203 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| gsk 1004723 | Homo sapiens (human) | Ki | 0.0398 | 3 | 3 |
| cep 26401 | Homo sapiens (human) | Ki | 9.8000 | 1 | 1 |
| nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| 2-((r-5-chloro-4-methoxymethylindan-1-yl)-1h-imidazole) | Homo sapiens (human) | Ki | 0.0830 | 1 | 1 |
| n,n-diallyl-5-methoxytryptamine | Homo sapiens (human) | Ki | 10.0000 | 2 | 2 |
| bix 02565 | Homo sapiens (human) | IC50 | 0.9140 | 1 | 0 |
| clozapine | Homo sapiens (human) | Ki | 0.0201 | 6 | 6 |
| olanzapine | Homo sapiens (human) | Ki | 0.0290 | 5 | 6 |
Drugs with Activation Measurements
Drugs with Other Measurements
[no title available]European journal of medicinal chemistry, , Apr-15, Volume: 168, 2019
[no title available]European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Structure-activity relationships in 1,4-benzodioxan-related compounds. 11. (1) reversed enantioselectivity of 1,4-dioxane derivatives in α1-adrenergic and 5-HT1A receptor binding sites recognition.Journal of medicinal chemistry, , Jan-24, Volume: 56, Issue:2, 2013
Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic α₁- and serotonine 5-HT1A receptors.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
Discovery of a new series of 5-HT1A receptor agonists.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 20, Issue:6, 2010
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9. From 1,4-benzodioxane to 1,4-dioxane ring as a promising template of novel alpha1D-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents.Journal of medicinal chemistry, , Oct-23, Volume: 51, Issue:20, 2008
trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines.Journal of medicinal chemistry, , Dec-06, Volume: 44, Issue:25, 2001
Phenylpiperazinylalkylamino substituted pyridazinones as potent alpha(1) adrenoceptor antagonists.Journal of medicinal chemistry, , Jul-19, Volume: 44, Issue:15, 2001
Structure-activity relationships in 1,4-benzodioxan-related compounds. 6. Role of the dioxane unit on selectivity for alpha(1)-adrenoreceptor subtypes.Journal of medicinal chemistry, , Jul-29, Volume: 42, Issue:15, 1999
WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors.Journal of medicinal chemistry, , Oct-07, Volume: 42, Issue:20, 1999
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.European journal of medicinal chemistry, , Feb-05, Volume: 211, 2021
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
The discovery of quinoline based single-ligand human HBioorganic & medicinal chemistry letters, , 12-15, Volume: 26, Issue:24, 2016
Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.Bioorganic & medicinal chemistry, , Oct-15, Volume: 20, Issue:20, 2012
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.Journal of medicinal chemistry, , Apr-14, Volume: 54, Issue:7, 2011
[no title available]European journal of medicinal chemistry, , Apr-15, Volume: 168, 2019
[no title available]European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Structure-activity relationships in 1,4-benzodioxan-related compounds. 11. (1) reversed enantioselectivity of 1,4-dioxane derivatives in α1-adrenergic and 5-HT1A receptor binding sites recognition.Journal of medicinal chemistry, , Jan-24, Volume: 56, Issue:2, 2013
Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic α₁- and serotonine 5-HT1A receptors.Journal of medicinal chemistry, , Jan-12, Volume: 55, Issue:1, 2012
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: structure-affinity/activity relationship at alpha1-adrenoceptor subtypes and at 5-HT1A receptors.European journal of medicinal chemistry, , Volume: 45, Issue:9, 2010
Discovery of a new series of 5-HT1A receptor agonists.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 20, Issue:6, 2010
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9. From 1,4-benzodioxane to 1,4-dioxane ring as a promising template of novel alpha1D-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents.Journal of medicinal chemistry, , Oct-23, Volume: 51, Issue:20, 2008
Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective alpha(1d)-adrenergic receptor antagonists.Journal of medicinal chemistry, , Apr-21, Volume: 48, Issue:8, 2005
New pyrimido[5,4-b]indoles as ligands for alpha(1)-adrenoceptor subtypes.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes.Journal of medicinal chemistry, , Apr-11, Volume: 45, Issue:8, 2002
Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.Bioorganic & medicinal chemistry letters, , May-07, Volume: 11, Issue:9, 2001
WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors.Journal of medicinal chemistry, , Oct-07, Volume: 42, Issue:20, 1999
Design, synthesis, and biological activity of prazosin-related antagonists. Role of the piperazine and furan units of prazosin on the selectivity for alpha1-adrenoreceptor subtypes.Journal of medicinal chemistry, , Nov-19, Volume: 41, Issue:24, 1998
4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.Bioorganic & medicinal chemistry letters, , Dec-02, Volume: 12, Issue:23, 2002
2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.Bioorganic & medicinal chemistry letters, , Feb-11, Volume: 12, Issue:3, 2002
2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.Bioorganic & medicinal chemistry letters, , Nov-05, Volume: 11, Issue:21, 2001
Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006
Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 14, Issue:22, 2004
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.Journal of medicinal chemistry, , Mar-15, Volume: 39, Issue:6, 1996
Synthesis and evaluation of 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a potent, peripherally acting alpha 2 adrenoceptor agonist.Journal of medicinal chemistry, , Aug-30, Volume: 39, Issue:18, 1996
Quinazoline based αEuropean journal of medicinal chemistry, , Aug-18, Volume: 136, 2017
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtJournal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.Journal of medicinal chemistry, , Volume: 30, Issue:1, 1987
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002
Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002
[no title available]Bioorganic & medicinal chemistry letters, , 05-15, Volume: 28, Issue:9, 2018
[no title available]Bioorganic & medicinal chemistry letters, , 02-15, Volume: 28, Issue:4, 2018
Synthesis, structure-activity relationship and biological evaluation of novel arylpiperzines as α1A/1D-AR subselective antagonists for BPH.Bioorganic & medicinal chemistry, , Dec-15, Volume: 23, Issue:24, 2015
2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.Bioorganic & medicinal chemistry letters, , Nov-05, Volume: 11, Issue:21, 2001
2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series.Bioorganic & medicinal chemistry letters, , Feb-25, Volume: 12, Issue:4, 2002
2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues.Journal of medicinal chemistry, , May-23, Volume: 45, Issue:11, 2002
2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides.Bioorganic & medicinal chemistry letters, , Nov-05, Volume: 11, Issue:21, 2001
Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998
Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.Journal of medicinal chemistry, , Sep-27, Volume: 39, Issue:20, 1996
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.European journal of medicinal chemistry, , Feb-05, Volume: 211, 2021
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HTMedChemComm, , Mar-01, Volume: 9, Issue:3, 2018
Quinazoline based αEuropean journal of medicinal chemistry, , Aug-18, Volume: 136, 2017
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015
Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 25, Issue:22, 2015
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 24, Issue:7, 2014
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 24, Issue:2, 2014
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.Bioorganic & medicinal chemistry, , May-15, Volume: 21, Issue:10, 2013
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.European journal of medicinal chemistry, , Volume: 63, 2013
New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine.Bioorganic & medicinal chemistry, , Oct-01, Volume: 19, Issue:19, 2011
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.Journal of medicinal chemistry, , Jan-13, Volume: 48, Issue:1, 2005
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.Journal of medicinal chemistry, , Nov-03, Volume: 48, Issue:22, 2005
Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors.Journal of medicinal chemistry, , Nov-06, Volume: 46, Issue:23, 2003
Phenylpiperazinylalkylamino substituted pyridazinones as potent alpha(1) adrenoceptor antagonists.Journal of medicinal chemistry, , Jul-19, Volume: 44, Issue:15, 2001
Design and synthesis of novel dihydropyridine alpha-1a antagonists.Bioorganic & medicinal chemistry letters, , Oct-04, Volume: 9, Issue:19, 1999
Novel adrenoceptor antagonists with a tricyclic pyrrolodipyridazine skeleton.Journal of medicinal chemistry, , Jan-14, Volume: 42, Issue:1, 1999
Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Dec-17, Volume: 41, Issue:26, 1998
Design, synthesis, and biological activity of prazosin-related antagonists. Role of the piperazine and furan units of prazosin on the selectivity for alpha1-adrenoreceptor subtypes.Journal of medicinal chemistry, , Nov-19, Volume: 41, Issue:24, 1998
4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.Journal of medicinal chemistry, , Aug-15, Volume: 40, Issue:17, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.Journal of medicinal chemistry, , Volume: 30, Issue:1, 1987
2,4-Diamino-6,7-dimethoxyquinazolines. 2. 2-(4-Carbamoylpiperidino) derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.Journal of medicinal chemistry, , Volume: 30, Issue:6, 1987
Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.Journal of medicinal chemistry, , Dec-10, Volume: 58, Issue:23, 2015
Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.Journal of medicinal chemistry, , Volume: 25, Issue:6, 1982
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.Journal of medicinal chemistry, , Volume: 22, Issue:6, 1979
[no title available]Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
[no title available]Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021
Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 30, Issue:20, 2020
Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.Bioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020
Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.Bioorganic & medicinal chemistry letters, , 02-15, Volume: 28, Issue:4, 2018
[no title available]European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.Bioorganic & medicinal chemistry, , 09-01, Volume: 25, Issue:17, 2017
Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.Bioorganic & medicinal chemistry letters, , 07-01, Volume: 26, Issue:13, 2016
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.European journal of medicinal chemistry, , Feb-05, Volume: 211, 2021
Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as αBioorganic & medicinal chemistry, , 11-01, Volume: 24, Issue:21, 2016
α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one.Bioorganic & medicinal chemistry, , May-01, Volume: 23, Issue:9, 2015
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones.Journal of medicinal chemistry, , Nov-18, Volume: 42, Issue:23, 1999
Identification of a dihydropyridine as a potent alpha1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate.Journal of medicinal chemistry, , Jul-02, Volume: 41, Issue:14, 1998
Design and synthesis of N-alkylated saccharins as selective alpha-1a adrenergic receptor antagonists.Bioorganic & medicinal chemistry letters, , Sep-22, Volume: 8, Issue:18, 1998
4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): a potent and selective alpha1b adrenergic receptor antagonist.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.Journal of medicinal chemistry, , Aug-15, Volume: 40, Issue:17, 1997
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.Journal of medicinal chemistry, , Aug-15, Volume: 40, Issue:17, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
[no title available]European journal of medicinal chemistry, , Apr-15, Volume: 168, 2019
1,3-Dioxane as a scaffold for potent and selective 5-HTEuropean journal of medicinal chemistry, , Aug-15, Volume: 176, 2019
Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptoJournal of medicinal chemistry, , May-26, Volume: 54, Issue:10, 2011
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: structure-affinity/activity relationship at alpha1-adrenoceptor subtypes and at 5-HT1A receptors.European journal of medicinal chemistry, , Volume: 45, Issue:9, 2010
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.Journal of medicinal chemistry, , 01-09, Volume: 63, Issue:1, 2020
[no title available]European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Structure-activity relationships in 1,4-benzodioxan-related compounds. 11. (1) reversed enantioselectivity of 1,4-dioxane derivatives in α1-adrenergic and 5-HT1A receptor binding sites recognition.Journal of medicinal chemistry, , Jan-24, Volume: 56, Issue:2, 2013
Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel α1-adrenoreceptor antagonists related to openphendioxan: synthesis, biological evaluation, and α1d computational study.Bioorganic & medicinal chemistry, , Oct-01, Volume: 18, Issue:19, 2010
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9. From 1,4-benzodioxane to 1,4-dioxane ring as a promising template of novel alpha1D-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents.Journal of medicinal chemistry, , Oct-23, Volume: 51, Issue:20, 2008
Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors.Journal of medicinal chemistry, , Nov-06, Volume: 46, Issue:23, 2003
1,3-dioxolane-based ligands as a novel class of alpha1-adrenoceptor antagonists.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Structure-activity relationships in 1,4-benzodioxan-related compounds. 6. Role of the dioxane unit on selectivity for alpha(1)-adrenoreceptor subtypes.Journal of medicinal chemistry, , Jul-29, Volume: 42, Issue:15, 1999
WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors.Journal of medicinal chemistry, , Oct-07, Volume: 42, Issue:20, 1999
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Absolute configuration of glycerol derivatives. 7. Enantiomers of 2-[[[2-(2,6-dimethoxyphenoxy)ethyl]amino]methyl]-1,4-benzodioxane (WB-4101), a potent competitive alpha-adrenergic antagonist.Journal of medicinal chemistry, , Volume: 22, Issue:9, 1979
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.Bioorganic & medicinal chemistry letters, , Sep-20, Volume: 14, Issue:18, 2004
Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998
[no title available]Bioorganic & medicinal chemistry letters, , 06-15, Volume: 28, Issue:11, 2018
Discovery of Quinazoline-Based Fluorescent Probes to α1-Adrenergic Receptors.ACS medicinal chemistry letters, , May-14, Volume: 6, Issue:5, 2015
Bioisosteric phentolamine analogs as potent alpha-adrenergic antagonists.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 15, Issue:21, 2005
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.Journal of medicinal chemistry, , Aug-15, Volume: 40, Issue:17, 1997
Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.Journal of medicinal chemistry, , Volume: 25, Issue:6, 1982
Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as αBioorganic & medicinal chemistry, , 11-01, Volume: 24, Issue:21, 2016
α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one.Bioorganic & medicinal chemistry, , May-01, Volume: 23, Issue:9, 2015
Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.Journal of medicinal chemistry, , Sep-27, Volume: 39, Issue:20, 1996
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.Journal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Radioligand and computational insight in structure - Activity relationship of saccharin derivatives being ipsapirone and revospirone analogues.Bioorganic & medicinal chemistry letters, , 06-15, Volume: 42, 2021
Indolebutylamines as selective 5-HT(1A) agonists.Journal of medicinal chemistry, , Sep-09, Volume: 47, Issue:19, 2004
Selective alpha-1a adrenergic receptor antagonists. Effects of pharmacophore regio- and stereochemistry on potency and selectivity.Bioorganic & medicinal chemistry letters, , Sep-22, Volume: 8, Issue:18, 1998
Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.Bioorganic & medicinal chemistry, , May-01, Volume: 16, Issue:9, 2008
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.Journal of medicinal chemistry, , Sep-15, Volume: 38, Issue:19, 1995
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
[no title available]Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021
Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.Bioorganic & medicinal chemistry letters, , 02-15, Volume: 28, Issue:4, 2018
[no title available]European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.Bioorganic & medicinal chemistry letters, , 07-01, Volume: 26, Issue:13, 2016
[no title available]Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021
Polypharmacology - foe or friend?Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013
Designed multiple ligands. An emerging drug discovery paradigm.Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
New pyrimido[5,4-b]indoles as ligands for alpha(1)-adrenoceptor subtypes.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.Journal of medicinal chemistry, , Sep-15, Volume: 38, Issue:19, 1995
The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH.European journal of medicinal chemistry, , Nov-01, Volume: 205, 2020
Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective αJournal of medicinal chemistry, , Oct-27, Volume: 59, Issue:20, 2016
Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as αBioorganic & medicinal chemistry, , 11-01, Volume: 24, Issue:21, 2016
Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.European journal of medicinal chemistry, , Volume: 45, Issue:12, 2010
(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 18, Issue:2, 2008
(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 17, Issue:14, 2007
(Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 17, Issue:12, 2007
Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.Journal of medicinal chemistry, , Aug-15, Volume: 40, Issue:17, 1997
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
[no title available]Bioorganic & medicinal chemistry, , 07-23, Volume: 26, Issue:12, 2018
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Synthesis and alpha(1)-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin.Bioorganic & medicinal chemistry, , Mar-15, Volume: 15, Issue:6, 2007
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006
Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
New potential uroselective NO-donor alpha1-antagonists.Journal of medicinal chemistry, , Aug-14, Volume: 46, Issue:17, 2003
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 25, Issue:22, 2015
New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine.Bioorganic & medicinal chemistry, , Oct-01, Volume: 19, Issue:19, 2011
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 20, Issue:2, 2010
Novel 4-phenylpiperidine-2,6-dione derivatives. Ligands for α₁-adrenoceptor subtypes.European journal of medicinal chemistry, , Volume: 46, Issue:7, 2011
1,3-dioxolane-based ligands as a novel class of alpha1-adrenoceptor antagonists.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Improving selectivity of dopamine D3 receptor ligands.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016
Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists.Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006
Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.Journal of medicinal chemistry, , Aug-15, Volume: 40, Issue:17, 1997
Novel 4-phenylpiperidine-2,6-dione derivatives. Ligands for α₁-adrenoceptor subtypes.European journal of medicinal chemistry, , Volume: 46, Issue:7, 2011
New pyrimido[5,4-b]indoles and [1]benzothieno[3,2-d]pyrimidines: high affinity ligands for the alpha(1)-adrenoceptor subtypes.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 16, Issue:24, 2006
New pyrimido[5,4-b]indoles as ligands for alpha(1)-adrenoceptor subtypes.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist.Journal of medicinal chemistry, , Sep-27, Volume: 39, Issue:20, 1996
7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists.Journal of medicinal chemistry, , May-18, Volume: 43, Issue:10, 2000
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
Design, Synthesis, and Biological Evaluation of Indoline and Indole Derivatives as Potent and Selective α1A-Adrenoceptor Antagonists.Journal of medicinal chemistry, , 04-28, Volume: 59, Issue:8, 2016
Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective αJournal of medicinal chemistry, , Oct-27, Volume: 59, Issue:20, 2016
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
Novel 2-imidazoles as potent and selective alpha1A adrenoceptor partial agonists.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
Synthesis, pharmacology and pharmacokinetics of 3-(4-aryl-piperazin-1-ylalkyl)-uracils as uroselective alpha1A-antagonists.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 13, Issue:11, 2003
Pharmacological options in the treatment of benign prostatic hyperplasia.Journal of medicinal chemistry, , Apr-25, Volume: 40, Issue:9, 1997
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
Synthesis and evaluation of 18F-labeled dopamine D3 receptor ligands as potential PET imaging agents.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 15, Issue:21, 2005
Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002
The discovery of quinoline based single-ligand human HBioorganic & medicinal chemistry letters, , 12-15, Volume: 26, Issue:24, 2016
Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.Bioorganic & medicinal chemistry, , Oct-15, Volume: 20, Issue:20, 2012
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.Journal of medicinal chemistry, , Apr-14, Volume: 54, Issue:7, 2011
Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 19, Issue:11, 2009
6,7-Dihydro-5H-pyrrolo[1,2-a] imidazoles as potent and selective alpha1A adrenoceptor partial agonists.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 19, Issue:11, 2009
Novel 2-imidazoles as potent, selective and CNS penetrant alpha1A adrenoceptor partial agonists.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 18, Issue:24, 2008
Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.Journal of medicinal chemistry, , Jun-29, Volume: 49, Issue:13, 2006
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential.Bioorganic & medicinal chemistry letters, , Aug-16, Volume: 14, Issue:16, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
[no title available]Bioorganic & medicinal chemistry letters, , 01-01, Volume: 31, 2021
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
Enables
This protein enables 3 target(s):
| Target | Category | Definition |
|---|
| alpha1-adrenergic receptor activity | molecular function | Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha1-adrenergic receptors; the activity involves transmitting the signal to the Gq alpha subunit of a heterotrimeric G protein. [GOC:cb, GOC:mah, IUPHAR_GPCR:1274] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| protein heterodimerization activity | molecular function | Binding to a nonidentical protein to form a heterodimer. [GOC:ai] |
Located In
This protein is located in 8 target(s):
| Target | Category | Definition |
|---|
| nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
| nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
| cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| caveola | cellular component | A membrane raft that forms small pit, depression, or invagination that communicates with the outside of a cell and extends inward, indenting the cytoplasm and the cell membrane. Examples include flask-shaped invaginations of the plasma membrane in adipocytes associated with caveolin proteins, and minute pits or incuppings of the cell membrane formed during pinocytosis. Caveolae may be pinched off to form free vesicles within the cytoplasm. [GOC:mah, ISBN:0721662544, PMID:16645198] |
| nuclear membrane | cellular component | Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space. [GOC:mah, GOC:pz] |
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 33 target(s):
| Target | Category | Definition |
|---|
| MAPK cascade | biological process | An intracellular protein kinase cascade containing at least a MAP kinase (MAPK). It starts with the activation of a MAP3K, and the consecutive activation of a MPK2K and a MAPK. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinase in the downstream tier to transmit a signal within a cell. [PMID:20811974, PMID:9561267] |
| negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of heart contraction as a result of the baroreceptor response to increased blood pressure. [ISBN:0721643949] |
| norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure | biological process | A process that results in a decrease in the diameter of an artery during the norepinephrine-epinephrine response to decreased blood pressure. [GOC:mtg_cardio, ISBN:0721643949] |
| positive regulation of heart rate by epinephrine-norepinephrine | biological process | The process in which the presence of epinephrine or norepinephrine in the bloodstream activates, maintains or increases the rate of heart contraction. [GOC:dph] |
| positive regulation of the force of heart contraction by epinephrine-norepinephrine | biological process | Any process that increases the force with which the cardiac muscles of the heart pump blood through the circulatory system as a result of the presence of epinephrine or norepinephrine in the bloodstream or released from the nerve endings. [GOC:dph, GOC:mtg_cardio] |
| apoptotic process | biological process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263] |
| smooth muscle contraction | biological process | A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Smooth muscle differs from striated muscle in the much higher actin/myosin ratio, the absence of conspicuous sarcomeres and the ability to contract to a much smaller fraction of its resting length. [GOC:ef, GOC:jl, GOC:mtg_muscle, ISBN:0198506732] |
| signal transduction | biological process | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. [GOC:go_curators, GOC:mtg_signaling_feb11] |
| G protein-coupled receptor signaling pathway | biological process | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor] |
| activation of phospholipase C activity | biological process | The initiation of the activity of the inactive enzyme phospolipase C as the result of The series of molecular signals generated as a consequence of a G protein-coupled receptor binding to its physiological ligand. [GOC:dph, GOC:mah, GOC:tb, PMID:8280098] |
| positive regulation of cytosolic calcium ion concentration | biological process | Any process that increases the concentration of calcium ions in the cytosol. [GOC:ai] |
| adult heart development | biological process | The process whose specific outcome is the progression of the adult heart over time, from its formation to the mature structure. [GOC:bf] |
| negative regulation of cell population proliferation | biological process | Any process that stops, prevents or reduces the rate or extent of cell proliferation. [GOC:go_curators] |
| response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| response to hormone | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus. [GOC:jl] |
| negative regulation of autophagy | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. [GOC:dph, GOC:tb] |
| positive regulation of cardiac muscle hypertrophy | biological process | Any process that increases the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division. [GOC:BHF, GOC:dph, GOC:tb] |
| positive regulation of synaptic transmission, GABAergic | biological process | Any process that activates, maintains or increases the frequency, rate or extent of GABAergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter gamma-aminobutyric acid (GABA). [GOC:mah] |
| intracellular signal transduction | biological process | The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell. [GOC:bf, GOC:jl, GOC:signaling, ISBN:3527303782] |
| positive regulation of MAPK cascade | biological process | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade. [GOC:go_curators] |
| positive regulation of action potential | biological process | Any process that activates or increases the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels. [GOC:go_curators] |
| positive regulation of vasoconstriction | biological process | Any process that activates or increases the frequency, rate or extent of vasoconstriction. [GOC:go_curators] |
| positive regulation of smooth muscle contraction | biological process | Any process that activates or increases the frequency, rate or extent of smooth muscle contraction. [GOC:go_curators] |
| calcium ion transport into cytosol | biological process | The directed movement of calcium ions (Ca2+) into the cytosol. [GOC:dph, GOC:tb] |
| positive regulation of cardiac muscle contraction | biological process | Any process that increases the frequency, rate or extent of cardiac muscle contraction. [GOC:dph, GOC:tb] |
| cell growth involved in cardiac muscle cell development | biological process | The growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state. [GOC:dph] |
| positive regulation of ERK1 and ERK2 cascade | biological process | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. [GOC:mah] |
| positive regulation of protein kinase C signaling | biological process | Any process that increases the frequency, rate, or extent of a series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound. [GOC:dph, GOC:tb] |
| pilomotor reflex | biological process | The reflex process in which the arrectores pilorum (hair follicle) muscles contract and cause the hair to stand erect. [GOC:BHF, PMID:21335239, Wikipedia:Pilomotor_reflex] |
| neuron-glial cell signaling | biological process | Cell-cell signaling that mediates the transfer of information from a neuron to a glial cell. This signaling has been shown to be mediated by various molecules released by different types of neurons, e.g. glutamate, gamma-amino butyric acid (GABA), noradrenaline, acetylcholine, dopamine and adenosine. [GOC:aruk, GOC:bc, PMID:10195197, PMID:10196584, PMID:10377338, PMID:10493741, PMID:11356870, PMID:11399439, PMID:15252819, PMID:27788368] |
| phospholipase C-activating G protein-coupled receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194] |
| adenylate cyclase-activating adrenergic receptor signaling pathway | biological process | An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process. [GOC:BHF, GOC:mah, GOC:signaling] |
| cell-cell signaling | biological process | Any process that mediates the transfer of information from one cell to another. This process includes signal transduction in the receiving cell and, where applicable, release of a ligand and any processes that actively facilitate its transport and presentation to the receiving cell. Examples include signaling via soluble ligands, via cell adhesion molecules and via gap junctions. [GOC:dos, GOC:mah] |